Living Cell Technologies Limited
Board and Management Team
The Board of Directors
Professor Bernie Tuch BSc, MBBS (Hons), FRACP, PhD, GAICD, Chair, Interim CEO
Robert Willcocks BA, LLM Independent Director
Professor Carolyn Sue AM MB, BS, PhD, FRACP Independent Director
Dr Andrew Kelly BVSc (Hons), MSc, PhD Independent Director
Mark Licciardo B Bus (Acc), GradDip CSP, FGIA, GAICD Company Secretary
Management Team
Professor Bernie Tuch Interim CEO
Dr Belinda Di Bartolo Chief Operating Officer
Mr Daya Uka BCom, CA Chief Financial Officer
The Board of Directors
 |
| Professor Bernie Tuch | BSc, MBBS (Hons), FRACP, PhD, GAICD, Chair, Interim CEO |
| | |
| Professor Tuch is an Honorary Professor at Monash University. Previously, he was a senior scientist with CSIRO Australia. He is a director of Sydney Cell Therapy Foundation Pty Limited, the not-for-profit Australian Foundation for Diabetes Research, and is a Specialist Practitioner, Endocrinology, at the Prince of Wales Private Hospital & St Vincent's Private Hospital, Sydney.
His experience includes capital raising to support his considerable research team and a large international scientific publication list. He has had previous scientific collaborations with LCT and knows the company's direction intimately.
Professor Tuch was chairman of the Remuneration and Nomination Committee until he became Interim CEO on 16 July 2021. He was appointed to the board on 20 July 2011, becoming Interim Chairman on 31 August 2018 and Executive Chairman on 11 November 2022. |
|
back to top
 |
| Robert Willcocks | BA, LLM Independent Director |
| | |
| Robert Willcocks is a senior executive with an extensive legal and business background working in particular with Australian listed public companies. He has Bachelor of Arts and Bachelor of Laws degrees from the Australian National University and a Master of Laws degree from the University of Sydney. Mr Willcocks was a partner with the law firm Stephen Jaques & Stephen (now King & Wood Mallesons) from 1980 until 1994, where he was a member of the Corporate Advisory Group with an emphasis on the mining and oil and gas sectors. As corporate adviser he has undertaken assignments in a range of industry sectors.
Mr Willcocks has been a director and Chairman of a number of Australian Securities Exchange (ASX) listed public companies. He is a former director of ASX listed ARC Exploration Limited, and Hong Kong Stock Exchange listed APAC Resources Ltd. He is also chairman and director of Trilogy Funds Management Ltd, a Responsible Entity under Australian law.
Mr Willcocks is chairman of the Audit and Compliance Committee and a member of the Remuneration and Nomination Committee.
He was appointed to the board on 29 March 2011. |
|
back to top
 |
| Professor Carolyn Sue AM | MB, BS, PhD, FRACP Independent Director |
| | |
| Dr Sue has an extensive background in neurological science and medicine in relation to chronic illnesses. She is the Head of Neuroscience Research at the Kolling Institute at Sydney's Royal North Shore Hospital, and Director of Neurogenetics, Director of the National Centre for Adult Stem Cell Research and a Senior Staff Specialist in the Department of Neurology at the Kolling Institute. She holds a M.B., B.S. from the University of New South Wales and a PhD from the University of Sydney and is a Professor at Sydney Medical School. She is also a Fellow of the Royal Australasian College of Physicians (FRACP) and an officer of the Asian-Oceanic Section of the International Movement Disorder Society.
Professor Sue was recognised as a Member in the General Division of the Order of Australia in the 2019 Queen's Birthday honours for her service to medicine.
Professor Sue was appointed to the board on 16 May 2019. |
|
back to top
 |
| Dr Andrew Kelly | BVSc (Hons), MSc, PhD Independent Director |
| | |
| Andrew Kelly has an extensive background in research, commercialisation and investment. In 2005 he co-founded BioPacificVentures, the first specialist venture fund in New Zealand and Australia to focus across the life sciences. In 2014 he broadened the business model to create BioPacific Partners, partnering with some of the largest global companies to invest and engage with local innovation. He has held a dozen board roles over the last 22 years all in businesses involved in life science innovation. Dr Kelly has strong networks across New Zealand and Australia and globally.
Dr Kelly spent the early part of his career in life sciences research and development in Australia and Canada and then led research institutes in Australia and New Zealand. He later led product development and then early stage investment at AgResearch. In this role he built deep engagement with the global investor community.
Dr Kelly was appointed to the board on 7 November 2019. |
|
back to top
 |
| Mark Licciardo | B Bus (Acc), GradDip CSP, FGIA, GAICD Company Secretary |
| | |
| Mark Licciardo is the founder and managing director of Mertons Corporate Services. He has extensive experience in working with Boards of Directors of high profile ASX listed companies in the areas of corporate governance, accounting & finance and company secretarial practices during a 30 year corporate career in banking and finance, funds management, investment, infrastructure development and in the establishment and management of a consulting business. A former company secretary of Top 50 ASX listed companies Transurban Group and Australian Foundation Investment Company Limited, Mark is also the former Chairman of the Governance Institute of Australia (GIA) Victoria division and Melbourne Fringe Festival and a current non-executive director of a number of public and private companies. |
|
back to top
Management Team
Professor Bernie Tuch, Interim CEO
|
Professor Tuch is an Honorary Professor at The University of Sydney and Monash University. Dr Tuch is also supervising a bioengineering diabetes cell therapy project at the University of Technology Sydney. Previously, he was a senior scientist with CSIRO Australia. He is a director of Sydney Cell Therapy Foundation Pty Limited, the not-for-profit Australian Foundation for Diabetes Research, and is a Specialist Practitioner, Endocrinology, at the Prince of Wales Private Hospital & St Vincent's Private Hospital, Sydney.
His experience includes capital raising to support his considerable research team and a large international scientific publication list. He has had previous scientific collaborations with LCT and knows the company's direction intimately.
Professor Tuch was chairman of the Remuneration and Nomination Committee until he became interim CEO on 16 July 2021. He was appointed to the board on 20 July 2011 and appointed interim chairman on 31 August 2018.
|
back to top
Dr Belinda Di Bartolo, Chief Operating Officer
 |
Dr Belinda Di Bartolo leads the planning and preparations for the third clinical trial of NTCELL in Parkinson's disease.
Dr Di Bartolo has 18 years' experience in health and medical research. She has a clear understanding of the translational pathway of research as well as knowledge of the regulatory processes, with experience in ethics and governance committees. Dr Di Bartolo, who is based in Sydney, has outstanding leadership and relationship skills and a fundamental passion for medical research.
Prior to joining LCT, Dr Di Bartolo was a research fellow at the Kolling Institute at the University of Sydney, NSW. She previously held research roles at SAHMRI, The Heart Research Institute and the University of New South Wales, NSW. She holds a Bachelor of Medical Science (Hons) and a PhD from the University of Sydney.
|
back to top
Daya Uka, BCom, CA Chief Financial Officer
 |
Mr Uka has had a varied career working in finance across a range of industries. He joined LCT from Millennium Copthorne Hotels. Daya has a wealth of experience working in ASX- and NZX-listed companies, product commercialisation, cost saving, managing fixed assets, audit as well as mergers and acquisitions. He has held roles at Vector, Pacific Retail Group, Auckland Gas, Carter Holt Harvey, Kmart and Progressive Enterprises.
Daya is a member of the Chartered Accountants of New Zealand and Australia and holds a Bachelor of Commerce from the University of Auckland. Daya joined LCT in 2016.
|
back to top
updated 24th October, 2022
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of
this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for
use on this website. All rights under applicable laws are hereby reserved. Reproduction
of this website in whole or in part without the express written permission of irasia.com Ltd
is strictly prohibited.
TERMS OF USE: Please read the Terms of Use governing the use
of our website.
|